Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers.

Johne A, Scheible H, Becker A, van Lier JJ, Wolna P, Meyring M.

Invest New Drugs. 2020 Mar 27. doi: 10.1007/s10637-020-00926-1. [Epub ahead of print]

PMID:
32221754
2.

Insights into Praziquantel metabolism and potential enantiomeric CYP-mediated drug-drug interaction.

Vendrell-Navarro G, Scheible H, Lignet F, Burt H, Luepfert C, Marx A, Abla N, Swart P, Perrin D.

Drug Metab Dispos. 2020 Mar 19. pii: dmd.119.089888. doi: 10.1124/dmd.119.089888. [Epub ahead of print]

3.

A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the "Metabolites in Safety Testing" Regulatory Guidance.

Schadt S, Bister B, Chowdhury SK, Funk C, Hop CECA, Humphreys WG, Igarashi F, James AD, Kagan M, Khojasteh SC, Nedderman ANR, Prakash C, Runge F, Scheible H, Spracklin DK, Swart P, Tse S, Yuan J, Obach RS.

Drug Metab Dispos. 2018 Jun;46(6):865-878. doi: 10.1124/dmd.117.079848. Epub 2018 Feb 27. Review.

PMID:
29487142
4.

Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors.

Scheible H, Kraetzer F, Marx A, Johne A, Wimmer E.

Drug Metab Dispos. 2017 Feb;45(2):174-182. doi: 10.1124/dmd.116.072934. Epub 2016 Dec 1.

PMID:
27934635
5.

Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.

von Richter O, Massimini G, Scheible H, Udvaros I, Johne A.

Br J Clin Pharmacol. 2016 Dec;82(6):1498-1508. doi: 10.1111/bcp.13078. Epub 2016 Sep 19.

6.

In vitro and in vivo drug disposition of cilengitide in animals and human.

Dolgos H, Freisleben A, Wimmer E, Scheible H, Krätzer F, Yamagata T, Gallemann D, Fluck M.

Pharmacol Res Perspect. 2016 Mar 17;4(2):e00217. doi: 10.1002/prp2.217. eCollection 2016 Apr.

7.

Metabolism and disposition of the αv-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans.

Becker A, von Richter O, Kovar A, Scheible H, van Lier JJ, Johne A.

J Clin Pharmacol. 2015 Jul;55(7):815-24. doi: 10.1002/jcph.482. Epub 2015 Mar 23.

PMID:
25683324
8.

Comparison of the in vitro and in vivo metabolism of Cladribine (Leustatin, Movectro) in animals and human.

Scheible H, Laisney M, Wimmer E, Javornik A, Dolgos H.

Xenobiotica. 2013 Dec;43(12):1084-94. doi: 10.3109/00498254.2013.791762. Epub 2013 Apr 29.

PMID:
23627543
9.

In vitro metabolite identification of ML3403, a 4-pyridinylimidazole-type p38 MAP kinase inhibitor by LC-Qq-TOF-MS and LC-SPE-cryo-NMR/MS.

Kammerer B, Scheible H, Zurek G, Godejohann M, Zeller KP, Gleiter CH, Albrecht W, Laufer S.

Xenobiotica. 2007 Mar;37(3):280-97.

PMID:
17624026
10.
11.

Overexpression, purification and characterization of SimL, an amide synthetase involved in simocyclinone biosynthesis.

Luft T, Li SM, Scheible H, Kammerer B, Heide L.

Arch Microbiol. 2005 May;183(4):277-85. Epub 2005 Apr 6.

PMID:
15812631
12.

A comparison of psychophysical methods in the investigation of foveal simultaneous brightness contrast.

DIAMOND AL, SCHEIBLE H, SCHWARTZ E, YOUNG R.

J Exp Psychol. 1955 Sep;50(3):171-4. No abstract available.

PMID:
13252192
13.

The role of overt errors in serial rote learning.

SCHEIBLE H, UNDERWOOD BJ.

J Exp Psychol. 1954 Mar;47(3):160-2. No abstract available.

PMID:
13152287

Supplemental Content

Loading ...
Support Center